AIM Current Deferred Revenue vs Capital Stock Analysis
| AIM Stock | USD 0.23 0.02 9.52% |
AIM ImmunoTech financial indicator trend analysis is way more than just evaluating AIM ImmunoTech prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AIM ImmunoTech is a good investment. Please check the relationship between AIM ImmunoTech Current Deferred Revenue and its Capital Stock accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
Current Deferred Revenue vs Capital Stock
Current Deferred Revenue vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AIM ImmunoTech Current Deferred Revenue account and Capital Stock. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between AIM ImmunoTech's Current Deferred Revenue and Capital Stock is 0.45. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capital Stock in the same time period over historical financial statements of AIM ImmunoTech, assuming nothing else is changed. The correlation between historical values of AIM ImmunoTech's Current Deferred Revenue and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of AIM ImmunoTech are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Current Deferred Revenue i.e., AIM ImmunoTech's Current Deferred Revenue and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.45 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Most indicators from AIM ImmunoTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.At this time, AIM ImmunoTech's Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Sales General And Administrative To Revenue is likely to grow to 109.87, while Issuance Of Capital Stock is likely to drop about 68.4 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 67K | 478K | 549.7K | 281.1K | Research Development | 7.7M | 7.0M | 10.9M | 6.9M |
AIM ImmunoTech fundamental ratios Correlations
Click cells to compare fundamentals
AIM ImmunoTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AIM ImmunoTech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 13.8M | 20.2M | 64.6M | 40.5M | 19.4M | 29.4M | |
| Short Long Term Debt Total | 6.4M | 2.3M | 149K | 837K | 718K | 682.1K | |
| Other Current Liab | 214K | 672K | 438K | 806K | 1.8M | 1.3M | |
| Total Current Liabilities | 1.1M | 1.1M | 673K | 1.4M | 8.7M | 9.1M | |
| Total Stockholder Equity | 12.9M | 61.3M | 56.9M | 38.5M | 10.2M | 9.7M | |
| Property Plant And Equipment Net | 7.3M | 6.7M | 4.2M | 1.0M | 824K | 782.8K | |
| Net Debt | 4.9M | (36.2M) | (31.9M) | (26.2M) | (4.7M) | (5.0M) | |
| Retained Earnings | (328.1M) | (342.0M) | (361.1M) | (380.5M) | (409.5M) | (389.0M) | |
| Accounts Payable | 472K | 383K | 198K | 377K | 6.4M | 6.8M | |
| Cash | 1.5M | 38.5M | 32.1M | 27.1M | 5.4M | 10.3M | |
| Non Current Assets Total | 9.8M | 24.3M | 7.5M | 4.2M | 4.8M | 8.5M | |
| Cash And Short Term Investments | 8.8M | 39.0M | 48.3M | 34.2M | 13.1M | 19.4M | |
| Common Stock Shares Outstanding | 3.6M | 31.8M | 47.3M | 48.0M | 48.6M | 51.0M | |
| Liabilities And Stockholders Equity | 13.8M | 20.2M | 64.6M | 40.5M | 19.4M | 29.4M | |
| Other Current Assets | 848K | 184K | 304K | 455K | 604K | 528.6K | |
| Other Stockholder Equity | 340.2M | 402.5M | 417.2M | 418.3M | 419.0M | 251.9M | |
| Total Liab | 7.3M | 3.3M | 820K | 2.0M | 9.1M | 9.6M | |
| Total Current Assets | 10.4M | 40.3M | 50.2M | 36.3M | 14.6M | 20.9M | |
| Short Term Debt | 252K | 47K | 37K | 178K | 446K | 423.7K | |
| Intangible Assets | 1.2M | 1.5M | 2.0M | 1.9M | 2.3M | 1.3M | |
| Non Currrent Assets Other | 1.4M | (46.3M) | 1.3M | 1.2M | 1.7M | 1.8M | |
| Net Receivables | 820K | 1.1M | 1.6M | 1.7M | 1.2M | 747.1K | |
| Short Term Investments | 7.3M | 501K | 16.2M | 7.1M | 7.6M | 11.5M | |
| Common Stock | 33K | 49K | 10K | 42K | 48K | 89.5K | |
| Non Current Liabilities Total | 6.2M | 2.2M | 147K | 659K | 495K | 470.3K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.